

MEDICAL RESEARCH LAW & POLICY REPORT & REG; INDEX-SUMMARY

— Vol. 8, No. 1-20, pp. 1-722
— Jan. 7, 2009 - Oct. 21, 2009

NOTE ON ALPHABETIZATION: *This subject index is arranged alphabetically word-by-word. For example, the heading NEW YORK precedes the heading NEWSPAPERS.*

A

AAHRPP (ASS'N FOR ACCREDITATION OF HUMAN RESEARCH PROTECTION PROGRAMS) *See* ACCREDITATION AND CERTIFICATION

ACCREDITATION AND CERTIFICATION

Conflict-of-interest standards, AAHRPP considers expanding, 389; final standards released, 654
Human protection program
—AAHRPP announces approvals for 2008, 18; 13 organizations accredited, 458; children's hospitals, 670
—Pfizer seeks accreditation, 172; program accredited, 278

ADVERSE EFFECTS

Seroquel maker accused of suppressing data on risks, 194

ADVERSE EVENTS

Clinical trials, guidance on reporting released by FDA, 39
Genetic basis for certain events, FDA releases data, 120

AIDS AND HIV

Pediatric research, drug trials, report finds no evidence of resulting foster children deaths, 93

ALABAMA

GINA rules, In Brief, 532

ALIENS

H-1B visas
—FY2010 cap not yet met, 278
—Grassley (R-Iowa) wants action on visa fraud, 683
—Overhaul. *See* LEGISLATION, FEDERAL, S 887
—Ph.D. graduates. *See* LEGISLATION, FEDERAL, HR 1791
—TARP, new requirements for employers issued, 244
—Univ. of Pittsburgh accused of bias (W.D. Pa.), 450
L-1 visas overhaul. *See* LEGISLATION, FEDERAL, S 887

ALOGLIPTIN

Diabetes guidance, FDA to apply, 201

ANALYSIS & PERSPECTIVE

Bay-Dole Act, 628
Stem cell research federal funding ban lifted, 253
Synthetic biology, 571

ANIMAL TESTING

Disclosure, USDA must release study data (D.D.C.), 661
EPA moving away from animal tests, 528
EU. *See* EUROPEAN UNION (EU)
Heartland Regional use of live cats at issue, 435
International agreement to reduce animal use signed, 317
"Random source" of dogs and cats, NIH does not need, report says, 424
Toxicological testing, federal advisory group discusses efforts, 457
UC Santa Cruz, FBI makes arrests in attacks on researchers, 162; 4 indicted (N.D. Cal.), 250; dismissal sought, 498

UCSF

—Animal Welfare Act suit dismissed (Cal. Ct. App.), 25; appealed (Cal.), 116; review denied (Cal.), 248
—Threatening researcher, activist sentenced (Cal. Super. Ct.), 126

ANTHRAX

Vaccine approval upheld (D.C. Cir.), 652

ANTIBIOTICS

Ketek maker accused of concealing dangers (E.D.N.Y.), 364

APPROVALS

Anthrax vaccine approval upheld (D.C. Cir.), 652

ARIZONA

Virtual tissue bank planned, 160

ARMED SERVICES

CIA experiments, veterans sue federal government (N.D. Cal.), 45

ATTORNEYS' FEES

Xenotransplantation, nonprofit seeking data from FDA eligible for attorney's fees (D.C. Cir.), 82

B

BIOLOGICS

Priorities for FDA outlined at conference, 342
Quality, new analytical methods and standards urged at House hearing, 663

BIOTECHNOLOGY *See* GENETICS AND BIOTECHNOLOGY

BIOTERRORISM *See* TERRORISM

BUDGET, U.S. *See specific agencies and departments*

C

CALIFORNIA

Animal testing
—UC Santa Cruz, FBI makes arrests in attacks on researchers, 162
—UCSF
——Animal Welfare Act suit dismissed (Cal. Ct. App.), 25; review denied (Cal.), 248
——Threatening researcher, activist sentenced (Cal. Super. Ct.), 126
Donated remains, UC Irvine accused of mishandling, dismissed (Cal.), 284
Grants, fair political practices agency issues warning, 54
Stem cell research
—China collaboration pact signed, 712
—Exemptions, In Brief, 621
—German collaboration, In Brief, 677
—Grant funding approved, 249; public comment sought, 285; training grants and disease team funding approved, 463
—In vitro induced pluripotent state research, In Brief, 433
—Intellectual property and revenues, 23; regulations consolidated, 591
—Model science curriculum, state to promote, 621
—Obama order favored, 205
—Oversight criticized, 462
UC ex-researcher alleges retaliation for inmate medical privacy concerns (Cal. Super. Ct.), 677
UCSF
—Grassley (R-Iowa) probes alleged financial impropriety, 461

CANADA

Radiopharmaceutical research, draft regs published, 245

CANCER

Breast cancer awareness. *See* LEGISLATION, FEDERAL, HR 995, HR 1691, HR 1740, HR 2279
Budget proposal would double NCI funding, 141
Chile and NCI enters research alliance, 458
Consent form for trial evaluated, 523
Fla. patient aid, In Brief, 496
Health improvement institute award, In Brief, 53
Leukemia, health plan must cover bone marrow transplant (N.D. Ohio), 145; coverage denial upheld (6th Cir.), 608
La. tumor registry, In Brief, 712
Muddled cancer study claim against CRO must be arbitrated (D. Ariz.), 393
N.J. research grants, In Brief, 593
State developments
—Florida
——Cigarette tax proposed to fund research, 160
——Financial aid, In Brief, 287
—Kan. registry, In Brief, 433
Univ. of Pittsburgh, prostate cancer research fraud alleged (W.D. Pa.), 607

CDC *See* CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)

CELEBREX

Arthritis drug, investors suit over alleged clinical study misrepresentations timely (3rd Cir.), 115
Unethical trial put patients at risk, report says, 198

CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)

Director named, 373
Grant closeout dates, HHS IG says CDC must observe, 165

CHILDREN'S HEALTH CARE

Challenges created for FDA and researchers, 292
Children's Hosp. of Philadelphia malpractice suits, disclosure of raw data on infant heart surgery denied (E.D. Pa.), 393
Enrollment opens for NIH study, 47
Heart deformity, summary judgment granted to MDs accused of malpractice (E.D. Pa.), 185
HIV/AIDS drug trials, report finds no evidence of resulting foster children deaths, 93
Identifying knowledge gaps on drugs and children, NIH plans program, 274
Medical monitoring claim over unapproved experimental implant may proceed (E.D. Pa.), 110
Obstacles to developing pediatric products, Special Report, 411
Stent implant, experimental procedure rulings ready for review (E.D. Pa.), 607
Tex. birth defect surveillance, In Brief, 593
Transitioning out of research. *See* LEGISLATION, FEDERAL, S 406

CHILE

Cancer, NCI enters research alliance, 458

CLINICAL TRIALS

Billing
—All-level coordination urged by experts, 170
—Audit and monitoring conference planned by BNA, 21
Blindness blamed on implant trial, suit dismissed (S.D. Ohio), 655
Celebrex. *See* CELEBREX
Certification of compliance, FDA issues final guidance, 78
Colorado insurance mandate approved by House, 158; signed, 374
Conflicts of interest, Medtronic trials under scrutiny, 465
Emerging nations called safe and ethical, 516
EU draft guidance issued, 487

CLINICAL TRIALS —Contd.

Experimental treatments
—Arrhythmia treatment was not unauthorized experimental surgery (U.S., rev sought), 553
—Framework for access for terminally ill patients suggested, 16
—Muscular dystrophy drug, ruling requiring maker to provide treatment to patient vacated (3rd Cir.), 11
—Seriously ill patients, FDA issues access rules, 553
Financial disclosures, HHS IG criticizes FDA oversight, 58
Gene therapy trial death confirmed, 486
GINA, subjects protected against discrimination by employers and insurers, HHS issues guidance, 271
Globalization raises issues, 153
Good clinical practice, most common mistakes outlined at conference, 334
Good Clinical Practices Initiative, FDA reaches agreement with EU agency, 519
Hemopure, proposed trial may be off, 12
hESC therapy trial for spinal cord injury cleared by FDA, 76
Human subject recruitment website, Pfizer collaborates with Private Access, 587
Hypertonic saline trial stopped, 363
Investigator can be criminally liable for not following FDA reporting requirements (5th Cir.), 128
IRBs. *See* INSTITUTIONAL REVIEW BOARDS (IRBs)
J&J gets warning from FDA, 596
Minn. considers ban on clinical trial participation by subjects in mental health commitment process, 127; bill signed, 374
Ore. insurance mandate, In Brief, 464
Orphan drugs, FDA grants to fund trials, 17
Outlook 2009, billing top issue, 5
Post-marketing studies
—Timetables met by most firms, FDA reports, 611
Principles for conducting trials released by PhRMA, 653
Rare diseases. *See* LEGISLATION, FEDERAL, HR 2866
Registries
—India, requires clinical trial registration, 367
—Use up, reporting requirements of journals and agencies cited, 291
Saline and trauma patients, trial halted by NIH after deaths, 231
Seroquel maker accused of suppressing data on risks, 194
Sponsor-CRS relationships, BNA plans audioconference, 125
Stem cell ALS trial, 21
Surgical ablation devices, FDA issues guidance, 671
Terminated trials, In Brief, 157
Therapeutic peptides clinical studies up, 397
Transparency, PhRMA revises research principles, 312
Trauma products, unauthorized trials alleged (E.D. Pa.), 466
Trovan. *See* TROVAN
Unauthorized trial of medical device, execs plead guilty (E.D. Pa.), 534
VIA-2291, In Brief, 431
Vytorin, Waxman (D-Cal) and Stupak (D-Mich) seek more information, 163; makers settle with states over data delay, 536
Warfarin, Medicare to cover clinical trial, 560
Xenotransplantation, nonprofit seeking data from FDA eligible for attorney's fees (D.C. Cir.), 82

COLLEGES AND UNIVERSITIES

Baylor, MD accuses IRB of not conducting proper investigation of claims about gene therapy experiments, remanded (S.D. Tex.), 11
Cornell false claims suit, one defense expert excluded (S.D.N.Y.), 60
Duke research grant administrative and clerical overcharges reported by HHS IG, 129
Emory
—Guidelines on financial conflicts issued, 434

—Psychiatry chair steps down over conflicts of interest, 25
Harvard
—Anti-p63 monoclonal antibodies, licensee lacked standing to sue (Fed. Cir.), 661
—Medical School to revise conflicts of interest policy, 161
—White House science advisor named, 17
Medical College of Ga.
—Professor's breach of employment contract award upheld (Ga. Ct. App.), 582
—Summary judgment granted for defendant in whistleblower research misconduct suit (S.D. Ga.), 142
Medical schools
—Conflicts of interest. *See* CONFLICTS OF INTEREST
—Specific schools. *See* specific schools, *this heading*
Open access journals, universities sign pact, 656
Stanford
—AIDS therapy, school lacks standing to make infringement claim (Fed. Cir.), 699
—Gene research, plagiarism alleged, 484
—Med school to post MD-industry ties, 277
UC ex-researcher alleges retaliation for inmate medical privacy concerns (Cal. Super. Ct.), 677
UC Irvine accused of mishandling donated remains, dismissed (Cal.), 284
UC Santa Cruz, FBI makes arrests in attacks on researchers, 162
UCLA professor accused of misusing foundation funds (Cal. Super. Ct.), 619
UCSF
—Animal Welfare Act suit dismissed (Cal. Ct. App.), 25; appealed (Cal.), 116; review denied (Cal.), 248
—Grassley (R-Iowa) probes alleged financial impropriety, 461
—Threatening researcher, activist sentenced (Cal. Super. Ct.), 126
Univ. of Iowa
—Conflicts of interest, new policy proposed, 81
—Cytomegalovirus promoter, Amgen sued over patents (S.D. Iowa), 484
—Humira, Abbott sued over patents (S.D. Iowa), 484
Univ. of Mich.
—Bias, colleges failed to show that patent issues were more than incidentally implicated in sex discrimination complaint (E.D. Mich.), 143
—Consortium to create new stem cell lines, 203
Univ. of Minn., conflict of interest, surgeon cleared, 594
Univ. of Pittsburgh
—National origin bias alleged (W.D. Pa.), 450
—Prostate cancer research fraud alleged (W.D. Pa.), 607
Univ. of R.I. gets NIH grant, 401
Univ. of Utah human gene patents challenged (S.D.N.Y.), 513
Univ. of Wash. announces genome analysis strategy, 588
Univ. of Wis.
—Computer processor patent, Intel settles (W.D. Wis.)
—704.1, 12
—Drug firm payment information at clinics, school to post, 12
Wayne State Univ. research director libel claim rejected (E.D. Mich.), 556
Weill Medical College settles grant fraud charges (S.D.N.Y.), 208
Yale settles false claims allegations over federal grants, 24

COLORADO

Clinical trial insurance mandate approved by House, 158; signed, 374

COMPARATIVE EFFECTIVENESS

Affordable choices bill, Senate panel rejects amendments, 453

AHRQ use of funds at issue, 275; agency will expand pre-existing research, 525
Baucus (D-Mont) and Grassley (R-Iowa) offer policy options, 324; will not ration care, Baucus says, 425
Coelho (D-Cal) to chair Partnership to Improve Patient Care, 199
Coronary revascularization, NIH awards grants to study, 708
Federal panel members named by HHS, 242; hears from industry, 323; "listening session," federal panel hears concerns, 370; needs of patients, focus urged, 426; data infrastructure pushed, 493
Funding. *See* LEGISLATION, FEDERAL, HR 1, S 1
Genetics panel at HHS reviews, 429
GOP bill. *See* LEGISLATION, FEDERAL, S 1259
Improving delivery system, IOM reports, 492
Innovation as focus urged for lawmakers, 325
Labels, FDA urged to include effectiveness data, 673
Lewin Group announces center for comparative effectiveness research, 525
Medicare, use of comparative effectiveness research urged, 84
New research paradigm urged, 368
Patient-centered solutions pushed, 50
Reform should include, conference told, 457; health reform to include, speakers says, 586; reform to include, 611; comparative effectiveness called essential to reform, 657
Savings and improved outcomes called key, 83; systems in other nations studied, 398; Cost savings questioned, 612
Stimulus bill privacy provisions may limit research, 451
Top issue for 2009 at NIH, 9

CONFERENCES AND MEETINGS

American Health Lawyers Ass'n, 97
Ass'n for the Accreditation of Human Research Projects, 172
Ass'n of Clinical Research Professionals, 334
Biotechnology Industry Organization, 407; 408; 409
FBI Synthetic Biology Conference, 571
Food and Drug Law Institute Annual Conf., 340; 341; 342
HHS meeting with researchers, 13
Luminex Plant xMAP USA Multiplexing Symposium, 371
National Institutes of Health Summit: The Science of Eliminating Health Disparities, 29
Natl. Library of Medicine, 395
Natl. Pharmaceutical Council, Entering a New Era of Evidence, 457
Opportunities and Challenges in the Emerging Field of Synthetic Biology, 489
Regulatory Affairs Professional Society, 595
Regulatory Affairs Professionals Society, 291; 292; 293
U.S. Chamber of Commerce, 83; 84

CONFLICTS OF INTEREST

AAHRPP considers expanding standards, 389; final standards released, 654
AdvaMed ethics code, many device makers adopt, 491
Association formed addresses harm caused by restrictions, 524
Complex conflicts may require customized approach, 430
Contracting agreements under federal scrutiny, 341
FDA
—Grassley (R-Iowa) seeks data on relationship with knee cartilage mesh maker, 193
—Panel member dismissed, Hinchey (D-NY) questions, 164
Financial disclosure pushed at conference, 209
Ghostwriting policies
—Grassley (R-Iowa) queries medical journals, 499
—HRT suit, discovery documents unsealed (E.D. Ark.), 559
Inevitability of financial conflicts described, 500

CONFLICTS OF INTEREST —Contd.

Investigator's financial conflicts discussed in journal, 583

IRBs, many lack clear policies, study finds, 273

J&J subpoenaed by N.J. Atty. Gen., 566

Medical schools

—Emory Univ.

—Guidelines on financial conflicts issued, 434

—Psychiatry chair steps down over conflicts of interest, 25

—Harvard Medical School to revise policy, 161

—Industry funding under Senate scrutiny, 535

—Medtronic inquiry, 2 MDs resign, 623

—Stanford med school to post MD-industry ties, 277

—UCLA investigates MD, 537

—Univ. of Iowa proposes new policy, 81

Medtronic clinical trials under scrutiny, 465

Orthopedic surgeon cleared of fabrication and falsification of data, 713

Physicians

—AstraZeneca to disclose payment to health care professionals who speak on its behalf, 397

—Codes of conduct urged by industry group, 148

—Company-MD ties, MedPAC reports, 195

—Gifts

—Conn. ban urged, 204

—Federal reporting bill. *See* LEGISLATION, FEDERAL, S 301

—Iowa ban approved by Senate, 248

—Mass. limits criticized, 54; compliance problems predicted, 90; medical organizations moving conferences out of Boston, 91; final rules adopted, 204

—Minn. ban, bill withdrawn, 286

—Vt. ban signed, 432

—Increased disclosure sought by IOM, 309

—Medical education funding, GSK limits, 669

—Military personnel, Grassley (R-Iowa) puts former

Army MD under scrutiny, 404; seeks med school data, 465; Army surgeon probed by Senate, 499;

Grassley want data from naval hospital, 534

—Minn. MDs, Forest Labs payments reported, 620

—NIH. *See* NATIONAL INSTITUTES OF HEALTH (NIH)

—Outlook 2009, top issue, 5

—Pfizer to disclose payments to health care professionals for consulting, speaking engagements, clinical trials, 120

Professional medical associations urged to reject industry funding, 272

Prosthesis maker payments not reported by all study authors, 705

Standard disclosure form offered for study authors, 702

State developments

—Gifts to MDs. *See* Physicians, *this heading*

—Massachusetts

—Fees for covered firms due Jul. 1, 433

—Hospital network to limit interaction with

industry, 285

—N.J. Atty. Gen. reaches agreement with Synthes, 375

Top issue for HHS IG in 2009, 57

Trial reports, In Brief, 283

Univ. of Minn. surgeon cleared, 594

Univ. of Wis. to post drug firm payment information at clinics, 12

CONGRESS, U.S.

Ed. Note: This heading is used for administrative actions only. For coverage of legislation by bill number, see LEGISLATION, FEDERAL. For information on measures not yet assigned bill numbers see specific subject headings.

Academic medicine caucus, In Brief, 710

CONNECTICUT

Gifts to MD, ban urged, 204

CONTRACT RESEARCH ORGANIZATIONS (CROs)

Muddled cancer study claim must be arbitrated (D.

Ariz.), 393

Outsourcing development work, Special Report, 344

CRIMINAL PROSECUTION

Biovail pleads guilty to conspiracy and kickbacks (D. Mass.), 683

Clinical investigator can be criminally liable for not following FDA reporting requirements (5th Cir.), 128

Fabricated grant audits sent to NIH, biotech firm director sentenced (W.D. Wash.), 375

Tissue seller sentenced for falsified data (E.D.N.C.), 716

Trauma products, unauthorized clinical trials alleged (E.D. Pa.), 466

Unauthorized trial of medical device, execs plead guilty (E.D. Pa.), 534

Whistleblowers, FDA scientists say they might have been targeted, 129

CROs *See* CONTRACT RESEARCH ORGANIZATIONS (CROs)

CYTOMEGALOVIRUS PROMOTER

Univ. of Iowa sues Amgen over patents (S.D. Iowa), 484

D

DEVICES *See* MEDICAL DEVICES

E

E-HEALTH

Breach notification, HHS issues interim final rule, 587

Challenges and benefits of electronic health records outlined, 395

La. electronic health records loan program bill signed, 531

Standards for IT, In Brief, 431

ENFORCEMENT POLICY

Academic medical centers, FDA crackdown may create opportunities, 98

Conflicts of interest. *See* CONFLICTS OF INTEREST

Federal Register format, In Brief, 711

HIPAA privacy rule. *See* HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA)

Pfizer to share data with EPA, 367

Recent administrative actions, chart, 27; 61; 94; 131; 166; 210; 251; 288; 335; 378; 406; 436; 467; 501; 538; 569; 597; 625; 685; 717

Registering clinical trials, enforcement of compliance planned without federal rule, 715

Shorter response times and more inspections expected from FDA, 595

Unsafe drugs, medical devices, and food products, FDA enforcement increase predicted, 340

ENVIRONMENTAL PROTECTION

Nanotechnology

—Limited participation in EPA program reported, 51

—Research strategy issued by EPA, 674

Toxicogenomic data studied by EPA, 399

ERISA

Autism therapy, equitable relief denied (E.D. Mich.), 186

EUROPEAN UNION (EU)

Animal testing

—Compliance, more animals predicted, higher costs estimated, 588

—Overhaul of testing regime planned, 365

—Unneeded testing reviewed, 563; agency issues clarification, 672

Clinical trials draft guidance issued, 487

Good Clinical Practices Initiative, FDA reaches agreement with EU agency, 519

R&D, EU signs off on public-private partnership projects, 397

EXPERIMENTAL TREATMENTS

Clinical trials. *See* CLINICAL TRIALS

Medical monitoring claim over unapproved experimental implant may proceed (E.D. Pa.), 110

EXPERT WITNESSES

Cornell false claims suit, one defense expert excluded (S.D.N.Y.), 60

F

FINANCIAL INDUSTRY STABILIZATION

Genome projects included in stimulus funding, 366

Grants, stimulus package subject of briefing, 238

NIH budget and stimulus funding. *See* NATIONAL INSTITUTES OF HEALTH (NIH)

FLORIDA

Cancer

—Cigarette tax proposed to fund research, 160

—Financial aid, In Brief, 287

Cancer patient aid, In Brief, 496

IRBs, In Brief, 496

Scripps opens facility, 160

FOOD AND DRUG ADMINISTRATION (FDA)

Appointments

—Medical device chief to resign, 558

—Nominee for commissioner should be familiar with drug industry and have “impeccable qualifications,” health coalition says, 14; consumer groups

comment, 124; nominees named, 187; hearings

planned, 325; Hamburg approved by panel, 364;

Hamburg approved by Senate, 364

—Policy advisor, In Brief, 590

—Von Eschenback to resign as commissioner, 14

Budget for FY2010

—Funding bill. *See* LEGISLATION, FEDERAL, HR 1997, S 1406

—House approves increase, 487

Civil penalties, In Brief, 166

Commissioner

—Ex-commissioner joins Center for Health

Transformation, 674

Conflicts of interest, panel member dismissal, Hincey

(D-NY) questions, 164

Enforcement increase predicted, 340

Grassley (R-Iowa) seeks clarification on employees

ability to discuss FDA issues, 237

Progress reported in improving quality of FDA

science, 408

Transparency pushed by new commissioner, 567

Whistleblowers, FDA scientists say they might have

been targeted for criminal investigation, 129

FRAUD AND ABUSE

Biovail pleads guilty to conspiracy and kickbacks,

settles false claims (D. Mass.), 683

BNA plans audioconference, In Brief, 22

Conflicts of interest. *See* CONFLICTS OF INTEREST

Economic crisis and funding, In Brief, 282

Grants. *See* GRANTS

Medicare copays by research sponsors, CMS

withdraws FAQ, 40

Misconduct in research

—Anesthesiologist accused of fabricating data, 209

—Conflicts of interest. *See* CONFLICTS OF INTEREST

—Down syndrome study had inadequate controls, 682

—Medical College of Ga., summary judgment granted

for defendant in whistleblower suit (S.D. Ga.), 142

—Orthopedic surgeon cleared of fabrication and

falsification of data, 713

—Procedures to prevent revised by FDA, 566

FRAUD AND ABUSE —Contd.

Misconduct in research —Contd.

—Timelines not as important as thorough investigation, HHS official says, 96

Outlook 2009, voluntary disclosure major issue, 5

Recoveries estimated by HHS IG, 434

Small businesses discussed at SBIR hearing, 567

Tissue seller sentenced for falsified data (E.D.N.C.), 716

Univ. of Pittsburgh, prostate cancer research fraud alleged (W.D. Pa.), 607

Visas. *See* ALIENS

G**GENETIC INFORMATION****NONDISCRIMINATION ACT (GINA)**

Ala. rules, In Brief, 532

Clinical trial subjects protected against discrimination by employers and insurers, HHS issues guidance, 271

Final rule expected from EEOC, 394; IRS, Labor

Dep't, HHS issue interim rules, 663

Ill. rules, In Brief, 532

Nev. rules, In Brief, 532

N.D. rules, In Brief, 532

Survey calls for more protection from discrimination and false ads, 561

Vt. rules, In Brief, 532

Wyo. rules, In Brief, 532

GENETICS AND BIOTECHNOLOGY

Antibiotic resistance, NIH guidelines at issue, 455

Baylor, MD accuses IRB of not conducting proper investigation of claims about gene therapy experiments, remanded (S.D. Tex.), 11

Biologics. *See* BIOLOGICS

Biotech crops, EU panel predicts increase, 617

Commercial applications of gene sequencing data no breach of agreement (N.D. Ill.), 485

Death in gene therapy trial confirmed, 486

Direct-to-consumer genetic tests

—False security raises concerns, 627

—Federal oversight sought, 488

—IVDs, tests likely to be considered, 626

Discrimination

—EEOC proposes bias ban, 149; final rules expected, 370

—GINA. *See* GENETIC INFORMATION NONDISCRIMINATION ACT (GINA)

—La. genetic testing rule, In Brief, 497

—N.M. rules, In Brief, 497

DNA molecule research, NIH releases biosafety resources, 524

Egg donor compensation, N.Y. panel approves, 496

Engineered organisms, USDA revising rules, seeks comments, 192

Net operating loss carryover tax break, industry group want one-time refund, 45

Patents

—Breast and ovarian cancer gene patents challenged (S.D.N.Y.), 358

—Effect on research

—Comments sought by HHS, 236

—Dire predictions not realized, journal reports, 236

—Exemption from infringement liability endorsed by HHS panel, 697

—Gene sequencing patents challenged (S.D.N.Y.), 580

—Heart disease gene patent awarded, 151

—Univ. of Utah human gene patents challenged (S.D.N.Y.), 513

Personalized medicine. *See* PERSONALIZED MEDICINE

Plant management, USDA issues draft auditing standard, 423

Recombinant DNA, NIH proposes expanded biosafety guidelines, 190

Security at biosafety labs, GAO reports, 562

Stanford accused of plagiarizing gene research, 484

State developments

—Ariz. plans virtual tissue bank, 160

—Mich. creating biobank for newborns, 432

Stimulus funding includes genome projects, 366

Swiss biotech crop ban extended, 494

Synthetic biology risks and benefits reviewed, 489

Test results transmitted between health systems, 666

Toxicogenomic data studied by EPA, 399

Univ. of Wash. announces genome analysis strategy, 588

Voluntary biotech quality management system, USDA launches pilot program to test, 83

GEORGIA

Governor announces medical innovation center, 401

GERMANY

Stem cell research collaboration with Cal., In Brief, 677

GIFTS *See* CONFLICTS OF INTEREST**GINA** *See* GENETIC INFORMATION NONDISCRIMINATION ACT (GINA)**GRANTS**

Bayh-Dole Act authority non-use, GAO reports, 522

Clinical and Translational Science Awards announced by NIH, 526

Closeout dates, HHS IG says CDC must observe, 165

Coronary revascularization, NIH awards grants to study effectiveness, 708

Financial conflicts, NIH may expand regulations, 357

Fraud

—Duke research grant administrative and clerical overcharges reported by HHS IG, 129

—Fabricated audits sent to NIH, biotech firm director sentenced (W.D. Wash.), 375

—Internal controls at NIH, HHS IG reports, 680

—Omeros denies false claims charges (W.D. Wash.), 714

—Weill Medical College settles grant fraud charges (S.D.N.Y.), 208

—Yale settles false claims allegations over federal grants, 24

Grant.gov web site revised by HHS, 527

Health informatics grants awarded by CDC, 671

Management a top issue for HHS IG in 2009, 57

Natl. Joint Replacement Registry, AHRQ awards grants, 527

Orphan drug clinical trials, FDA grants to fund, 17

Pediatric devices, In Brief, 675

Recovery Act grants awarded by NIH, 649

Small businesses. *See* LEGISLATION, FEDERAL, HR 2965

State developments

—Cal. fair political practices agency issues warning, 54

—New Jersey

—Brain injury research grants, In Brief, 402

—Cancer research grants, In Brief, 593

—Developmental disabilities research grants, In Brief, 593

—Spinal cord research, In Brief, 287; announced, In Brief, 712

—Wash. issues grants for R&D, 55

Stem cell research. *See generally* STEM CELL RESEARCH

Stimulus package includes funding, 188; subject of briefing, 238

Univ. of R.I. gets NIH grant, 401

Web application system, GAO reports, 520

Web tool announced by NIH, 614

H**HEALTH AND HUMAN SERVICES DEPARTMENT (HHS)**

Appointments

—Comparative effectiveness panel members named by HHS, 242

—Daschle withdraws name, Baucus (D-Mont) and Kennedy (D-Mass) remain committed to health reform, 123; Sebelius nominated, 150; Senate action delayed, 280; Sebelius approved, 312

—Health IT coordinator named, 244

—Surgeon General nominated, 494; Senate panel approves, 708

CDC. *See* CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)

Civil rights unit revises web site, 125

FDA. *See* FOOD AND DRUG ADMINISTRATION (FDA)

Funding. *See* LEGISLATION, FEDERAL, HR 3293

Innovations, HHS seeks to encourage, 13; biomedical innovation, outgoing HHS official comments, 82

NIH. *See* NATIONAL INSTITUTES OF HEALTH (NIH)

OHRP. *See* OFFICE OF HUMAN SUBJECT PROTECTION (OHRP)

Regulatory agenda released, 359

Terrorism countermeasures funding, GAO reports, 522

HEALTH CARE REFORM, FEDERAL

Daschle pledges to work with both parties on reform, 48

Effectiveness research. *See* COMPARATIVE EFFECTIVENESS

Research role, In Brief, 373

HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA)

BNA plans audioconference, 201

Privacy rule

—Enforcement by HHS civil rights office announced, 537

—Guidance on health information networks offered by HHS, 21

—Inadequate and impediment to research, Institute of Medicine panel says, 112

—Invasions of privacy and security breaches remain obstacles, study finds, 279

HEMOPURE

Blood substitute, proposed trial may be off, 12

HHS *See* HEALTH AND HUMAN SERVICES DEPARTMENT (HHS)**HIPAA** *See* HEALTH INSURANCE

PORTABILITY AND ACCOUNTABILITY ACT (HIPAA)

HORMONE REPLACEMENT THERAPY (HRT)

Ghostwriting by maker, documents unsealed (E.D. Ark.), 559

HUMAN SUBJECT PROTECTION

Criteria for enrollment, MDs and RNs favor patient benefits, 706

Decisionally impaired research subjects. *See*

INFORMED CONSENT

Draft guidelines, OHRP developing, 541

Economic recession and White House could change goals of OHRP, 172

Exempt research, OHRP posts FAQs, 704

GAO says system is vulnerable to ethical manipulation, 227; ramifications of GAO probe, Special Report, 294

Harmonizing rules, federal panel to study, 541

Heart risk guidance issued by FDA, 19

India, unethical human experiments, new laws to address, 316

Multi-agency jurisdiction, OHRP offers guidance, 716

Noncompliance list updated by OHRP, 163

Obama dissolves bioethics council, 454

Oversight, new administration plans policy changes, 214

HUMAN SUBJECT PROTECTION —Contd.

Pfizer seeks accreditation for human research protection program, 172; program accredited, 278
Pulmonary sickle-cell study halted due to safety issues, 518
Russian convicts, use in clinical trials banned, 529
State developments
—Minn. considers ban on clinical trial participation by subjects in mental health commitment process, 127; bill signed, 374
—N.H. proposal, In Brief, 621
—Va. rules, In Brief, 532
Trends
—Ethical protection of human study participant becoming major issue, 407
—Outlook 2009, top issue, 5

HUMIRA

Univ. of Iowa sues Abbott over Humira patents (S.D. Iowa), 484

I

ILLINOIS

Autism, In Brief, 433
GINA rules, In Brief, 532

IN VITRO DIAGNOSTIC DEVICES (IVDs) *See* MEDICAL DEVICES

INDIA

Clinical trial registration required, 367
Unethical human experiments, new laws to address, 316

INFLUENZA

Swine flu
—Funding sought by White House, 315
—Respirators, Institute of Medicine recommends, 616
Vaccine
—H1N1, In Brief, 529
—New method to make, HHS contracts to develop, 459

INFORMATION NETWORKS AND TECHNOLOGY

Better, faster research due to data sharing predicted by NCI official, 240
BNA plans audioconference on health IT funding, 201
Genetic test results transmitted between health systems, 666
Grants for health informatics award by CDC, 671
Internet. *See* INTERNET

INFORMED CONSENT

Blindness blamed on implant trial, suit dismissed (S.D. Ohio), 655
Cancer trial consent form evaluated, 523
Experimental stent implant, heart patient's claims dismissed (E.D. Pa.), 76; reconsideration denied, 420
Heart valves
—Repair, clarification, 22
—Unapproved heart valve marketing, Grassley (R-Iowa) queries FDA, 376
Human tissue product documents, attorney-client privilege waived in suit over illegal use of body parts (D.N.J.), 16
Impaired decisionmaking, recommendations approved by HHS panel, 215
Pacemaker implanted as part of NIH experiment, failure-to-warn claim may proceed (D. Del.), 389
Unfair competition and consumer remedies claims dismissed (S.D. Cal.), 609
VA, one-third of consent forms non-compliant, 403

INSTITUTIONAL REVIEW BOARDS (IRBs)

Accountability remains an issue at OHRP, 707
Assurances and registration, HHS clarifies policy, 364

Clinical trials

—Fraudulent clinical trial, IRBs claims House panel conducted illegal sting, 207
—Guidance on reporting released by FDA, 39
Conflicts of interest, many IRBs lack clear policies, study finds, 273
External IRBs, In Brief, 156
Fake study, Coast Independent shut down, 333
Fla. rule, In Brief, 496
GAO says system is vulnerable to ethical manipulation, 227; ramifications of GAO probe, Special Report, 294
Liability for violations, OHRP seeks comments, 189
Registration
—Database, FDA suggests updates, 667
—Final rule issued by FDA and OHRP, 41; deadline, In Brief, 589

INTELLECTUAL PROPERTY

Access limited by institutional material transfer agreements, 47
Government-funded articles. *See* LEGISLATION, FEDERAL, HR 801
Ischemia research, Pfizer to appeal trade secrets verdict (Cal. Super. Ct.), 26
Obstetrics journal article authorship dispute, summary judgment granted for defendant (E.D. Mich.), 78
Patents. *See* PATENTS
Stem cell research, In Brief, 23
Trademarks, mouse strain for human cell engraftment, infringement alleged (N.D. Cal.), 77
Traditional knowledge, WIPO endorse compromise, 709

INTERNATIONAL DEVELOPMENTS *See also* specific countries

Clinical trials, globalization raises issues, 153
Russia-U.S. cooperation pact, In Brief, 495

INTERNET

BNA Convergence launched, 401
CMS launched health IT website, 459
HHS civil rights unit revises web site, 125
NIH social science, In Brief, 53
Tech transfer, In Brief, 399

IOWA

Physician gifts ban approved by Senate, 248

IPLEX

ALS patients get access, 195

IRBs *See* INSTITUTIONAL REVIEW BOARDS (IRBs)

IVDs (IN VITRO DIAGNOSTIC DEVICES) *See* MEDICAL DEVICES

J

JURISDICTION

Trovan clinical trial claims may be tried in U.S. (2nd Cir.), 73

K

KANSAS

Cancer registry, In Brief, 433

KETEK

Antibiotic maker accused of concealing dangers (E.D.N.Y.), 364

L

LEGISLATION, FEDERAL

Ed. Note: This heading covers bills with assigned numbers. For information on measures not yet assigned numbers, see specific subject headings.

HR

—**1**, American Recovery and Reinvestment Act, includes comparative effectiveness research, House approves, S 1 is companion, 75; signed with NIH budget hike, 109
—**554**, Natl. Nanotechnology Initiative Amendments Act, Gordon (D-Tenn) would reauthorize, 46; House approves, 118
—**756**, Natl. Pain Care Policy Act, would authorize more research, education, and training on chronic pain, House panel approves, 193
—**801**, Fair Copyright in Research Works Act, Conyers (D-Mich), would protect government-funded articles, 114
—**820**, Nanotechnology Advancement and New Opportunities (NANO) Act, Honda (D-Cal.), would promote development and responsible stewardship, 122
—**873**, Stem Cell Research Improvement Act, DeGette (D-Colo) and Castle (R-Del), would increase funding, 112
—**995**, Mammogram and MRI availability Act, — hearing held, 710
—**1105**, Omnibus spending bill, includes FY2009 NIH funding, House approves, GOP lawmakers urge veto, 147; signed, 185
—**1541**, Small Business Act and the Small Business Investment Act, would extend program, 313
—**1545**, Permanent R&D tax credit, Boccieri (D-Ohio) and Lee (R-NY), 243
—**1691**, Breast Cancer Patient Protection Act, hearing held, 710
—**1740**, Breast Cancer Education and Awareness Requires Learning Young Act, hearing held, 710
—**1791**, Stopping Trained in America Ph.D.s from Leaving the Economy Act, Flake (R-Ariz), would provide H-1B visa cap exemption, 278
—**2279**, Eliminating Disparities in Breast Cancer Treatment Act, hearing held, 710
—**2747**, Technology Development and Outreach Act, Halvorson (D-Ill), House panel approves, 421
—**2767**, Investing in Tomorrow's Technology Act, Graves (R-Mo), House panel approves, 421
—**2769**, Commercializing Small Business Research and Development Act, Bright (D-Ala), House panel approves, 421
—**2772**, SBIR and STTR Enhancement Act, Schock (R-Ill), House panel approves, 421
—**2813**, Knee and Hip Replacement Act, Pascrell (D-NJ) and Doggett (D-Tex), would create national registry, 427
—**2866**, Improving Access to Clinical Trials Act, would modify SSI rules for patients with rare diseases, Markey (D-Mass) and Stearns (R-Fla), 452
—**2965**, Enhancing Small Business Research and Innovation Act, would allow firms backed by venture capital funds to apply for grants, House panel approves, 448; House approves, 483
—**2997**, FDA funding approved by Senate, In Brief, S 1406 is companion, 564; conference report approved, 708
—**3293**, HHS funding, House approves, 530
S
—**1**, American Recovery and Reinvestment Act, includes comparative effectiveness research, H 1 is companion, 75
—**301**, Physician Payment Sunshine Act, Kohl (D-Wis) and Grassley (R-Iowa), would require firms to report payments and gifts to MDs, 79; sponsors seek more disclosure at NIH, 486
—**406**, Nino's Act, would require access to medical care for children who transition out of research, 114
—**487**, Stem Cell Research Enhancement Act, Harkin (D-Iowa) and Specter (R-Pa), would remove funding limits, 146
—**887**, H-1B and L-1 Visa Reform Act, Durbin (D-Ill) and Grassley (R-Iowa), would overhaul guestworker program, 327

LEGISLATION, FEDERAL —Contd.

§—Contd.

- 914**, Cures Acceleration Network (CAN) Act, Specter (D-Pa), would create agency to advance science into practice, 315
- 1233**, SBIR/STTR Reauthorization Act, Senate panel approves, 448; Senate approves, 483
- 1259**, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act, Kyl (R-Ariz) and McConnell (R-Ky), would prevent rationing of care, 426
- 1373**, Federal Research Public Access Act, Cornyn (R-Tex) and Lieberman (D-Conn), would provide free online access to federally-funding project results, 454
- 1406**, FDA funding approved by Senate, In Brief, HR 2297 is companion, 564
- 1482**, Natl. Nanobusiness Alliance, Kerry (D-Mass), would reauthorize nanotechnology initiative, 526
- 1513**, SBIR extension, Landrieu (D-La), approved, 519

LOUISIANA

- Electronic health records loan program bill signed, 531
- Genetic testing rule, In Brief, 497
- Tumor registry, In Brief, 712

M

MARYLAND

- Nanotechnology funding cuts approved, 530
- Private-sector stem cell research funding considered, 159
- Stem cell research funding hike proposed by governor, 89; funding approved by General Assembly, 330; grant cuts approved, 530

MASSACHUSETTS

- Community benefits of nonprofits, Boston mayor wants probe, 23
- Conflicts of interest
 - Fees for covered firms due Jul. 1, 433
 - Gifts to MDs, limits criticized, 54; compliance problems predicted, 90; medical organizations moving conferences out of Boston, 91; final rules adopted, 204
 - Hospital network to limit interaction with industry, 285
- High-risk biological agents, ban proposed in Cambridge, 531
- Life sciences initiative, applications accepted, 90

MEDICAL DEVICES

- Aseptic isolators, attorneys' fees awarded in defamation claim (S.D. Ind.), 585
- Hospital research costs, HHS improperly excluded, 554
- In vitro diagnostic devices (IVDs)
 - Direct-to-consumer genetic test likely to be considered IVDs, 626
 - Guidance issued by FDA, 614
- Investigational device exemption, FDA offers draft guidance, 328
- Knee and hip replacement registry. *See* LEGISLATION, FEDERAL, HR 2813
- Knee injury treatment, FDA did not follow established protocol in review and clearing, 703
- Lab safety standards unenforced by FDA, watchdog group says, 154
- Premarket notification, FDA program under scrutiny, 671
- Unauthorized trial of medical device, execs plead guilty (E.D. Pa.), 534
- Waxman (D-Cal) wants probe of FDA clearance of knee device, 404

MEDICARE

- Comparative effectiveness research urged, 84

- Fraud, copays by research sponsors, CMS withdraws FAQ, 40
- FY2010 teaching hospital payment cuts opposed, 394
- Warfarin, Medicare to cover clinical trial, 560

MENTAL HEALTH

- Minn. considers ban on clinical trial participation by subjects in mental health commitment process, 127; bill signed, 374

MICHIGAN

- Biobank for newborns, state plans, 432
- Infection control at hospitals evaluated, 530
- Stem cell research tracking and reporting considered, 565
- Univ. of Mich. failed to show that patent issues were more than incidentally implicated in sex discrimination complaint (E.D. Mich.), 143

MINNESOTA

- Human subject protection, state considers ban on clinical trial participation by subjects in mental health commitment process, 127; signed, 374
- Physician gift ban, bill withdrawn, 286
- Privacy, families sue over Health Dep't storage of newborn blood and DNA, 203

MISCONDUCT IN RESEARCH *See* FRAUD AND ABUSE

N

NANOTECHNOLOGY

- Environmental issues. *See* ENVIRONMENTAL PROTECTION
- Epidemiologic studies, NIOSH addresses, 200
- Framework for evaluating, FDA developing, 293
- International developments
 - Spain creates research lab, In Brief, 86; Spain and Portugal launch nanotech center, 529
 - U.K. review finds gaps in global research on environmental, health, and safety questions, 326
- Limited participation in EPA program reported, 51
- Md. funding cuts approved, 530
- Natl. Nanotechnology Initiative
 - Agencies respond to criticism, 155
 - Collaboration planned by FDA and research institutions, 199
 - Reauthorization. *See* LEGISLATION, FEDERAL, HR 554, S 1482
- Responsible stewardship. *See* LEGISLATION, FEDERAL, HR 820
- Workshop planned, In Brief, 86

NATIONAL INSTITUTES OF HEALTH (NIH)

- Animal testing, NIH does not need "random source" of dogs and cats, report says, 424
- Appointments, Senate panel approves director, 519; Senate confirms, 556
- Bayh-Dole Act authority non-use, GAO reports, 522
- Biennial report released, 49
- Budget
 - Allergy and infectious disease institute to get stimulus funding, 392
 - Cancer proposal would double NCI funding, 141
 - FY2010 budget proposed, 361; House panel approves, 487
 - GOP leaders raise conflict of interest concerns, 229
 - Harkin (R-Iowa) ponders effect of stimulus funding after 2010, 391; Specter (R-Pa) and Harkin want more funding, 420
 - Omnibus bill. *See* LEGISLATION, FEDERAL, HR 1105
 - Recovery Act spending, HHS IG to report, 679
 - Stimulus funding at issue, 557
 - Top issue for 2009, 9
 - Use of funds, House hears testimony on stimulus package, 234
- Comparative effectiveness a top issue for 2009, 9

Conflicts of interest

- Grantees financial conflicts, NIH may expand regulations, 377
- Revision of rules predicted, 97; proposed rule will expand monitoring, 311
- Stimulus package, GOP leaders raise conflict of interest concerns, 229
- Top issue for 2009, 9
- Director named, 482
- Grants. *See* GRANTS
- Pacemaker implanted as part of NIH experiment, failure-to-warn claim may proceed (D. Del.), 389
- Peer review a top issue for 2009, 9
- Project officer failed to show removal was retaliatory (D. Md.), 581
- Public access to research results, compliance problems continue, 152
- Risk management, GAO reports, 681
- Social science web site, In Brief, 53
- Translational research office urged by Parkinson's group, 668

NEVADA

- GINA rules, In Brief, 532

NEW HAMPSHIRE

- Human subject protection proposal, In Brief, 621

NEW JERSEY

- Angioplasty demonstration project, community hospital regulations upheld (N.J. Super. Ct.), 619
- Brain injury research grants, In Brief, 402
- Developmental disabilities research grants, In Brief, 593
- Spinal cord research grants, In Brief, 287; announced, In Brief, 712

NEW MEXICO

- Genetic discrimination, In Brief, 497

NEW YORK

- Egg donor compensation, panel approves, 496

NIGERIA

- Trovan clinical trial claims
 - Hearing planned on claim that Pfizer tried to circumvent victims' attorneys (Conn. Super. Ct.), 362
 - Jurisdiction, claims may be tried in U.S. (2nd Cir.), 73; (U.S., rev sought), 516
 - Kano settles with Pfizer, 513
 - Settlement reported, 117; settlement said near, 276

NIH *See* NATIONAL INSTITUTES OF HEALTH (NIH)

NORTH DAKOTA

- GINA rules, In Brief, 532

O

OFF-LABEL USE

- Medical devices, whistleblower alleges unapproved use (S.D. W.Va.), 130
- "Reprint practices," FDA issues guidance, 42

OFFICE OF HUMAN SUBJECT PROTECTION (OHRP)

- Economic recession and White House could change goals of OHRP, 172

OKLAHOMA

- Criminal penalties for stem cell research, veto stands, 331
- Reporting rule for stem cell research, In Brief, 161; adopted, 496; system created, In Brief, 621

OREGON

- Clinical trial insurance mandate, In Brief, 464

ORGAN TRANSPLANTS

Bone failure and illegally obtained human tissue, too late to amend pleadings (D.N.J.), 233; production of documents ordered (D.N.J.), 318

ORPHAN DRUGS

Clinical trials, FDA grants to fund, 17

P

PATENTS

Adipose tissue stem cells, later contributors not inventors (Fed. Cir.), 515
AIDS therapy, Stanford lacks standing to make infringement claim (Fed. Cir.), 699
Anti-p63 monoclonal antibodies, licensee lacked standing to sue (Fed. Cir.), 661
Apparatus and method for collecting and validating clinical trial data, subject matter jurisdiction sufficient (D.N.J.), 144
Bayh-Dole Act authority non-use, GAO reports, 522
Computer processor, Intel settles with Univ. of Wisconsin organization (W.D. Wis.), 704
Cytomegalovirus promoter, Univ. of Iowa sues Amgen over patents (S.D. Iowa), 484
Genes. *See* GENETICS AND BIOTECHNOLOGY
Humira, Univ. of Iowa sues Abbott over patents (S.D. Iowa), 484
Intel donation did not create license (W.D. Wis.), 662
Mouse strain for human cell engraftment, infringement alleged (N.D. Cal.), 77
Stem cell transfers license, claim for milestone payment rejected (W.D. Tenn.), 235
Technology and innovation awards planned at White House, 675
Univ. of Mich. failed to show that patent issues were more than incidentally implicated in sex discrimination complaint (E.D. Mich.), 143

PAXIL

Birth defects
—Heart defect, jury awards \$2.5M (Pa. Ct. C. P.), 701
Birth defects blamed on drug, production of study correspondence ordered (D. Mass.), 652

PERSONALIZED MEDICINE

Integration of drug development and diagnostics remains slow, 409
Multi-agency initiative urged, 666
R&D advocates push, 369

PHYSICIANS

Conflicts of interests. *See* CONFLICTS OF INTEREST

PORTUGAL

Human tissue and cell handling law approved, 248
Public umbilical cord stem cell bank announced, 85

PRIVACY AND CONFIDENTIALITY

Confidentiality Coalition expresses concerns about information technology, 20
Consumer choice, Leavitt focuses on health information technology, 19
HIPAA. *See* HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA)
Minn. families sue over Health Dep't storage of newborn blood and DNA, 203
Safeguards must balance patient privacy and public health, 197
Sentinel initiative, In Brief, 430
UC ex-researcher alleges retaliation for inmate medical privacy concerns (Cal. Super. Ct.), 677

PRODUCT LIABILITY

Cholesterol drug unfavorable trial results, class action settled (D.N.J.), 163

Silicone gel prostheses, FDA approval after implantation, strict liability claim barred (M.D. Tenn.), 232
Trovan. *See* TROVAN

Q

QUALITY ASSURANCE

Best care practices, improved research and well-linked institutions needed, Senate panel told, 121
Voluntary biotech quality management system, USDA launches pilot program to test, 83

R

RADIOACTIVE MATERIAL

Cesium Chloride, NRC plans no ban on sources, 328

RESEARCH AND DEVELOPMENT (R&D)

Agenda released by HHS, 359
Autism, In Brief, 433
Barton (R-Tex) seeks funding data, In Brief, 618
Better, faster research due to data sharing predicted by NCI official, 240
BNA plans conference on contract research groups, 247
Canadian radiopharmaceutical research, draft regs published, 245
Chronic pain. *See* LEGISLATION, FEDERAL, HR 756
Clinical trials. *See* CLINICAL TRIALS
Comparative effectiveness. *See* COMPARATIVE EFFECTIVENESS
Contract research groups, BNA plans audiocconference, 156
Council for American Innovation formed, 240
CROs. *See* CONTRACT RESEARCH ORGANIZATIONS (CROs)
Disparities, strategies to address discussed at conference, 29
Economic benefits of research outlined by Research!America, 239
EU signs off on public-private partnership projects, 397
Funding
—Nobel winners urge funding hike, 80
—Outlook 2009, funding top issue, 5
—Web tool announced by NIH, 614
FY2011 budget priorities, OMB emphasizes science, 560
Gephardt offers policy platform, 427
Health care reform, In Brief, 373
Infection prevention plan developed at HHS, 18
Iplex, ALS patients get access, 195
Misconduct. *See* FRAUD AND ABUSE
Nanotechnology. *See* NANOTECHNOLOGY
NASA and NIH, In Brief, 283
Open access journals, universities sign pact, 656
Portugal, human tissue and cell handling law approved, 246
President's science panel members named, 319
Rare and neglected diseases, NIH program announced, 396
Research integrity training program, NSF implementation program published, 584
Responsible research guide, In Brief, 247
Russia-U.S. cooperation pact, In Brief, 495
Small businesses
—Enhancement. *See* LEGISLATION, FEDERAL, HR 2772
—Fraud and abuse discussed at SBIR hearing, 567
—House panel holds hearings, 421
—Improvements to SBIR suggested, 52; final book issued, In Brief, 201; funding pushed, 455
—Investment. *See* LEGISLATION, FEDERAL, HR 1541, HR 2767
—Outreach. *See* LEGISLATION, FEDERAL, HR 2747
—Reauthorization of SBIR and STTR. *See* LEGISLATION, FEDERAL, HR 2965, S 1233, S 1513

—Revitalization. *See* LEGISLATION, FEDERAL, HR 2769
Social benefits of Bayh-Dole reviewed, 490
Spanish researchers moving to private sector, rules issued, 460
State initiatives
—Fla. cigarette tax proposed to fund research, 160
—Ga. governor announces medical innovation center, 401
—Mass. life sciences initiative, applications accepted, 90
—Va neurotrauma trust fund, In Brief, 92; final rule, 593
—Wash. issues grants for R&D, 55
Transformative research
—Funding issues examined, 615
Transformative research
—Gordon (D-Tenn) supports additional models for fostering, 153
Transition to treatment. *See* LEGISLATION, FEDERAL, S 914
Translational Genomic Research Institute and Van Andel form partnership to accelerate discoveries from lab to patient care, 121
Translational research, funding scarcity questioned, 613
Transparency in science pushed by bipartisan panel, 561
Voluntary health organizations and funding, book addresses, 200
White House wants more R&D funding, 314; sustainability of funding questioned, 319

RHODE ISLAND

Univ. of R.I. gets NIH grant, 401

RIMONABANT

Obesity drug securities fraud suit dismissal appealed (S.D.N.Y.), 701

RUSSIA

Convicts, use in clinical trials banned, 529

S

SAFETY

Biosafety a top issue for HHS IG in 2009, 57
Drug-coat stents work better for elderly heart disease patients, 241
Gene therapy trial death confirmed, 486
Hemopure, proposed trial may be off, 12
High-risk biological agents, ban proposed in Cambridge, Mass., 531
Hypertonic saline trial stopped, 363
Infection control at Mich. hospitals evaluated, 530
Medical devices, lab safety standards unenforced by FDA, watchdog group says, 154
Outlook 2009, post-marketing surveillance key issue, 5
Pulmonary sickle-cell study halted due to safety issues, 518
Sentinel Initiative at FDA, Senators want updates, 49; privacy concerns, In Brief, 430
Seroquel maker accused of suppressing data on risks, 194
Waxman (D-Cal) wants probe of FDA clearance of knee device, 404

SBIR (SMALL BUSINESS INNOVATION RESEARCH) *See* RESEARCH AND DEVELOPMENT (R&D)

SECURITIES

Celebrex, investors suit over alleged clinical study misrepresentations timely (3rd Cir.), 115
Disclosure, thorough process needed to avoid SEC trouble, 321
Prostate drug, investors accuse maker of false statements (S.D.N.Y.), 165

SECURITIES—Contd.

Stem cell research misstatements alleged by SEC (W.D. Wash.), 623

SEROQUEL

Antipsychotic maker accused of suppressing data on risks, 194

SILICONE GEL PROTHESES

FDA approval after implantation, strict liability claim barred (M.D. Tenn.), 232

SOUTH KOREA

Embryonic stem cell research
—Jail sought for scientist, 594
—Revival, panel delays, 122

SPAIN

Nanotechnology research lab created, In Brief, 86
Researchers moving to private sector, rules issued, 460

SPECIAL REPORTS

CROs and outsourcing of development work, 344
IRBs, ramifications of GAO probe, 294
Pediatric products, obstacles to developing, 411

STEM CELL RESEARCH

Adipose tissue stem cells, later contributors not inventors (Fed. Cir.), 515
Allogeneic bone marrow transplant coverage denial upheld (6th Cir.), 698
ALS trial, 21
China collaborating with Cal., 712
DeGette (D-Colo) to offer legislation, 74
Funding
—Castle (R-Del) and DeGette (D-Colo) plan bill, 650
—Draft guidance from NIH limits funding to research with cells left over from fertility treatments, 307; limits raise concerns, 387; final guidance allows use of discarded embryos, 479
—Federal funding ban lifted, 183; implications, Analysis & Perspective, 253; agencies urged to adopt NIH guidelines, 518
—Increase. See LEGISLATION, FEDERAL, HR 873
—Removing limits. See LEGISLATION, FEDERAL, S 487
—State funding. See State developments, *this heading*
—Top issue for 2009 at NIH, 9
Generation of pluripotent stem cells, new method discovered, 147
German collaboration with Cal., In Brief, 677
hESC therapy trial for spinal cord injury cleared by FDA, 76
License on stem cell transfers, claim for milestone payment rejected (W.D. Tenn.), 235
Outlook 2009, top issue, 5
Portugal creating public umbilical cord stem cell bank, 85
Requests for stem cell lines, NIH accepting, 656
South Korea, embryonic stem cell research revival, panel delays, 122
State developments
—California
—China collaboration pact signed, 712
—Exemptions, In Brief, 621
—German collaboration, In Brief, 677
—Grant funding approved, 249; public comment sought, 285; training grants and disease team funding approved, 463
—Intellectual property and revenues, In Brief, 23; regulations consolidated, 591
—Model science curriculum, state to promote, 621
—Obama order favored, 205
—Oversight criticized, 462
—Maryland
—Hike proposed by governor, 89; funding approved by General Assembly, 330; grant cuts approved, 530
—Private-sector research, funding considered, 159
—Mich. tracking and reporting considered, 565

—Mo., challenge to funding rejected (Mo. Cir. Ct.), 87
—N.M. bill to permit research defeated, 249
—Oklahoma
—Criminal penalties for research, veto stands, 331
—Reporting rule, In Brief, 161; adopted, 496; system created, In Brief, 621
—Tex. grant rules, In Brief, 621
—Va. bioscience bill passed by Senate without stem cell amendments, 126; Assembly approves compromise, 158
Univ. of Mich. consortium to create new stem cell lines, 203
Universities, firms, advocates form coalition to push research, 520

STTR (SMALL BUSINESS TECHNOLOGY TRANSFER) See RESEARCH AND DEVELOPMENT (R&D)

SUPREME COURT, U.S.

Clinical trials
—Arrhythmia treatment was not unauthorized experimental surgery (rev sought), 553
—Trovan Nigerian clinical trial claims may be tried in U.S. (rev sought), 516

SWITZERLAND

Biotech crop ban extended, 494

T

TAXATION

R&D acquisitions, accounting rules sought, 616
R&D credit
—Guidance on R&D credit, IRS supplements, 85
—Permanent R&D credit. See LEGISLATION, FEDERAL, HR 1545
—Small business support permanent R&D credit, 490

TERRORISM

Chemist seeks access to select agents (D.D.C.), 659
Dual-use threats, concerned scientists may have overreacted by excluding foreigners from labs, report says, 116
HHS countermeasures funding, GAO reports, 522
High-containment biolabs, GAO reports on oversight, 658
Misuse of select agents, NRC/NIH report on preventing, 669
Security at biolabs may hinder international collaboration, 196
Synthetic biology, Analysis & Perspective, 571

TEXAS

Birth defect surveillance, In Brief, 593
Stem cell grant rules, In Brief, 621

TRADEMARKS

Mouse strain for human cell engraftment, infringement alleged (N.D. Cal.), 77

TROVAN

Nigerian clinical trial claims
—Hearing planned on claim that Pfizer tried to circumvent victims' attorneys (Conn. Super. Ct.), 362
—Jurisdiction, claims may be tried in U.S. (2nd Cir.), 73; (U.S., rev sought), 516
—Kano settles with Pfizer, 513
—Settlement reported, 117; settlement said near, 276

U

UNITED KINGDOM (UK)

Cell therapies, studies urge use, 281
Electronic medical records can be used to test efficacy of disease treatments, study finds, 123
Nanotechnology, review finds gaps in global research on environmental, health, and safety questions, 326

V

VACCINES

Anthrax vaccine approval upheld (D.C. Cir.), 652
Flu, HHS contracts to develop new method make, 459
H1N1 trials, In Brief, 529

VERMONT

GINA rules, In Brief, 532
Physician gift ban signed, 432

VETERAN'S AFFAIRS

Informed consent, one-third of consent forms non-compliant, 403

VIRGINIA

Bioscience bill passed by Senate without stem cell amendments, 126; Assembly approves compromise, 158
Human subject protection, In Brief, 532
Neurotrauma trust fund, In Brief, 92; final rule, 593

VYTORIN

Cholesterol drug clinical trials, Waxman (D-Cal) and Stupak (D-Mich) seek more information, 163
Unfavorable trial results, class action settled (D.N.J.), 163

W

WARFARIN

Anticoagulant drug, Medicare to cover clinical trial, 560

WASHINGTON

Grants issued for R&D, 55

WISCONSIN

Computer processor patent, Intel settles with Univ. of Wis. organization (W.D. Wis.), 704

WYOMING

GINA rules, In Brief, 532

Z

ZETIA

Cholesterol drug unfavorable trial results, class action settled (D.N.J.), 163